Q32 Bio (QTTB) Cash & Equivalents Growth (3y) (2020 - 2026)

Q32 Bio (QTTB) Cash & Equivalents Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Q32 Bio 215.94 Mn 165.19 Mn - 107.91%

Historic Data

Download Data
DateValue
Mar 31, 2026 107.91%
Dec 31, 2025 12.43%
Sep 30, 2025 4.35%
Jun 30, 2025 -32.23%
Mar 31, 2025 -35.86%
Dec 31, 2024 -81.97%
Sep 30, 2024 -2.41%
Jun 30, 2024 -6.00%
Mar 31, 2024 3.42%
Dec 31, 2023 -70.44%
Sep 30, 2023 -68.42%
Jun 30, 2023 -50.73%
Mar 31, 2023 -65.98%
Dec 31, 2022 -14.85%
Sep 30, 2022 -17.75%
Jun 30, 2022 14.67%
Mar 31, 2022 82.47%
Dec 31, 2021 40.25%
Sep 30, 2021 36.32%
Jun 30, 2021 7.38%